Zacks Investment Research on MSN3d
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER ...
pharmaphorum3y
FDA stifles Merck's cough drug gefapixant, asking for more data
Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...
pharmaphorum7d
After cough drug setback, Merck partners Hyfe's tracking app
It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...
Trevi Shares Climb On Positive Results for Chronic Cough Treatment
The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...
The Lancet3d
Placebo responses in clinical trials of refractory chronic cough: mechanisms, challenges, and mitigation strategies
Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...
Yahoo Finance4d
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two complete response letters (CRL) from the FDA. While the agency issued the ...
Nasdaq3d
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
Trevi is also conducting the phase IIb CORAL study, which is evaluating the drug in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. Data from this study is expected in the first ...